source
- FDA approves Priovant's Lisraya (brepocitinib) for rare skin disease dermatomyositisThe U.S. Food and Drug Administration has cleared the first oral targeted treatment for dermatomyositis, a rare and disabling skin disorder. The medication, brepocitinib, will be sold under the br…
- AstraZeneca and Ionis gene silencer Wainua fails trial after patients also took Pfizer heart drugAt the ESC Congress in Munich, a high‑profile trial of the gene‑silencing therapy Wainua, developed by AstraZeneca and Ionis, was reported to have failed. The failure was linked to participants co…